

RECONCILIATION OF SHARE CAPITAL AUDIT FOR THE QUARTER ENDED 30th SEPTEMBER, 2024
(Regulation 76 of SEBI (Depository and Participant) Regulations, 2018)

1.	For the quarter ended	SEPTEMBER30, 2024				
2.	ISIN	INE03QK01018				
3.	Face Value	Re. 1.00/- each				
4.	Name of the Company	SUVEN PHARMACEUTICALS LIMITED				
5.	Registered Office Address	# 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India Tel: 91 22 61539999				
6.	Correspondence Address	# 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India				
7.	Telephone & Fax No.	Ph: 040 – 23549414/3311				
8.	Email Address	investorservices@suvенpharm.com				
9.	Names of the Stock exchanges where the Company's Securities are listed.	BSE Limited National Stock Exchange of India Ltd				
		Number of shares		% of Total Issued Capital		
10.	Issued Capital	25,45,64,956		100.00%		
11.	Listed Capital (exchange wise) (as per Company Records)	25,45,64,956–NSE		100.00%		
		25,45,64,956–BSE		100.00%		
12.	Held in dematerialized form in CDSL	1,23,37,966		4.85%		
13.	Held in dematerialized form in NSDL	24,18,39,919		95.00%		
14.	Physical	3,87,071		0.15%		
15.	Total No. of shares (12+13+14)	25,45,64,956		100.00%		
16.	Reasons for difference if any between (10&11, 10& 15, 11 & 15)	NIL				
17.	Certifying the details of changes in share capital during the quarter under consideration as per Table Below					
Particulars*	No. of Shares	Applied or not applied for listing	Listed on Exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Approval pending for stock exchange (Specify names)
NIL	NIL	NIL	NIL	NIL	NIL	NIL

OFFICE :

Plot No. 143, Flat No. 301, SV's Kausalya Complex, Rajeev Nagar, Hyderabad - 45



